MDx/CDx Focus: NanoString Kicks off Second PAM50 Validation Study; MDxHealth ... - GenomeWeb
MDx/CDx Focus: NanoString Kicks off Second PAM50 Validation Study; MDxHealth .
NanoString Initiates Second Clinical Validation Study for Breast Cancer Assay - MarketWatch (press release)
NanoString Initiates Second Clinical Validation Study for Breast Cancer AssayMarketWatch (press release)The ABCSG8 study, initiated in 1996, demonstrated that compared to treatment with tamoxifen alone, sequential adjuvant treatment with tamoxifen followed by anastrozole in postmenopausal women with hormone receptor-positive early-stage breast cancer .
The Downside of Chemoprevention for Breast Cancer - Medscape
The Downside of Chemoprevention for Breast CancerMedscapeIn this study, both tamoxifen and raloxifene were shown to be effective in reducing breast cancer risk.
Collaborative study looks for clues on hard-to-treat breast cancer - R & D Magazine
R & D MagazineCollaborative study looks for clues on hard-to-treat breast cancerR & D MagazineSome types of breast cancer can be successfully treated with drugs such as tamoxifen, but treatment for a type of breast cancer more common in young and black women is still limited to radiation and general chemotherapy.
MicroRNAs in breast cancer play a role in development of resistance to tamoxifen - News-Medical.net
MicroRNAs in breast cancer play a role in development of resistance to tamoxifenNews-Medical.